These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 23599147)
21. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Ho HL; Chang FP; Ma HH; Liao LR; Chuang YT; Chang-Chien YC; Lin KY; Chou TY Respirology; 2013 Nov; 18(8):1261-70. PubMed ID: 23796143 [TBL] [Abstract][Full Text] [Related]
22. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue. Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505 [TBL] [Abstract][Full Text] [Related]
23. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544 [TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266 [TBL] [Abstract][Full Text] [Related]
25. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809 [TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405 [TBL] [Abstract][Full Text] [Related]
27. Detecting EGFR alterations in clinical specimens-pitfalls and necessities. Isaksson S; Bendahl PO; Salomonsson A; Jönsson M; Haglund M; Gaber A; Jirström K; Jönsson P; Borg A; Johansson L; Staaf J; Planck M Virchows Arch; 2013 Dec; 463(6):755-64. PubMed ID: 24158511 [TBL] [Abstract][Full Text] [Related]
28. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Park HS; Jang MH; Kim EJ; Kim HJ; Lee HJ; Kim YJ; Kim JH; Kang E; Kim SW; Kim IA; Park SY Mod Pathol; 2014 Sep; 27(9):1212-22. PubMed ID: 24406864 [TBL] [Abstract][Full Text] [Related]
29. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T; Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746 [TBL] [Abstract][Full Text] [Related]
30. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215 [TBL] [Abstract][Full Text] [Related]
31. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Bhargava R; Chen B; Klimstra DS; Saltz LB; Hedvat C; Tang LH; Gerald W; Teruya-Feldstein J; Paty PB; Qin J; Shia J Cancer; 2006 Apr; 106(8):1857-62. PubMed ID: 16532444 [TBL] [Abstract][Full Text] [Related]
32. Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency. Wang J; Andrici J; Sioson L; Clarkson A; Sheen A; Farzin M; Toon CW; Turchini J; Gill AJ Hum Pathol; 2016 Sep; 55():83-90. PubMed ID: 27184481 [TBL] [Abstract][Full Text] [Related]
33. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status. Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125 [TBL] [Abstract][Full Text] [Related]
34. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441 [TBL] [Abstract][Full Text] [Related]
35. [Mutation-specific antibodies for detection of epidermal growth factor receptor mutations in patients with lung adenocarcinoma]. Zhang Q; Zhang J Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):168-72. PubMed ID: 23769435 [TBL] [Abstract][Full Text] [Related]
36. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. Ragazzi M; Tamagnini I; Bisagni A; Cavazza A; Pagano M; Baldi L; Boni C; Cantile F; Barbieri F; Nicoli D; Sartori G; de Biase D; Gardini G; Rossi G J Clin Pathol; 2016 May; 69(5):440-7. PubMed ID: 26553934 [TBL] [Abstract][Full Text] [Related]
38. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Ambrosini-Spaltro A; Campanini N; Bortesi B; Azzoni C; Naldi N; Ampollini L; Tiseo M; Ardizzoni A; Rusca M; Carbognani P; Silini EM Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):356-62. PubMed ID: 22710815 [TBL] [Abstract][Full Text] [Related]
39. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668 [TBL] [Abstract][Full Text] [Related]